/

Organon & Co.

OGN US

OGN USOrganon & Co.

United States Composite

18.83

USD

+0.22

(+1.18%)

3.99EPS Dil.

4.70P/E

4.81BMarket Cap

6.12%Div. Yield

Next Earnings

May 6

Ex-Dividend Date

February 23

Dividend Date

March 14

Held by Insiders

0.13%

Held by Institutions

79.65%

Short % of Float

3.80%

YTD Yield

-25.19%

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

LT Borrowings

8,722

8,646

8,751

LT Finance Leases

- -

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

256

Market Capitalization

5,318

4,437

3,686

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

3,958

4,050

4,508

Cash, Cash Equivalents & STI

326

414

693

Accounts Receivable, Net

1,672

1,648

1,744

Inventories

1,199

1,186

1,315

Total Current Liabilities

2,387

2,491

2,918

Payables & Accruals

2,379

2,483

2,909

ST Debt

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

0.00%

-8.12%

1.44%

Net Income, GAAP

0.00%

-8.29%

11.56%

Free Cash Flow

0.00%

1.88%

164.00%

Total Cash Common Dividend

- -

1.38%

Total Equity

- -

92.15%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

1,506

1,595

1,600

1,603

6,304

2022

1,567

1,585

1,537

1,485

6,174

2023

1,538

1,608

1,519

1,598

6,263

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

1.58

1.68

1.27

0.80

5.33

2022

1.37

0.92

0.89

0.42

3.61

2023

0.70

0.95

0.23

2.14

4.01

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

0.29

0.28

0.57

2022

0.28

0.29

1.14

2023

0.29

1.15

Company Description

CEO: Mr. Kevin Ali
Full Time Employees: 10,000
Sector: Healthcare
Industry: Drug Manufacturers—General
Address: 30 Hudson Street Jersey City NJ United States 07302
CIK: 0001821825
Website: www.organon.com
Business: Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

Company News

Zacks
7 days ago
Earnings Preview: Organon (OGN) Q1 Earnings Expected to Decline
Zacks
8 days ago
Organon (OGN) Surpasses Market Returns: Some Facts Worth Knowing
CNBC
8 days ago
Not all dividend strategies are the same. How to choose the best one for you
Zacks
10 days ago
Organon (OGN) Beats Stock Market Upswing: What Investors Need to Know
Zacks
16 days ago
Should WisdomTree U.S. SmallCap Dividend ETF (DES) Be on Your Investing Radar?
Zacks
17 days ago
Organon (OGN) Advances While Market Declines: Some Information for Investors
Zacks
20 days ago
Molina (MOH) Wins Deal to Serve Michigan's Medicaid Members
Zacks
20 days ago
Play Safe! S&P 500 is Teasingly Close to its 50 DMA: 3 Picks
Zacks
23 days ago
Why HCA Healthcare (HCA) is a Smart Addition to Your Portfolio
Zacks
24 days ago
Why the Market Dipped But Organon (OGN) Gained Today
Yahoo
24 days ago
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
Yahoo
24 days ago
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
Zacks
a month ago
Encompass Health (EHC) Plans a 50-Bed Facility to Serve Texas
Zacks
a month ago
UnitedHealth (UNH) to Roll Out Medical Claims Software Soon
Zacks
a month ago
Here's Why You Should Retain Centene (CNC) Stock for Now
Zacks
2 months ago
Markets Dip but it's Time to Buy These Low-Risk High-Income Stocks
Zacks
2 months ago
Centene (CNC), Pearl Health Unite to Enhance Value-Based Care
Zacks
2 months ago
Here's Why You Should Add Cigna (CI) Stock to Your Portfolio
Zacks
2 months ago
Teladoc Health (TDOC) Unveils Solution to Ease Weight Loss
Yahoo
2 months ago
On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's health

Company Description

CEO: Mr. Kevin Ali
Full Time Employees: 10,000
Sector: Healthcare
Industry: Drug Manufacturers—General
Address: 30 Hudson Street Jersey City NJ United States 07302
CIK: 0001821825
Website: www.organon.com
Business: Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

Company News

Zacks
7 days ago
Earnings Preview: Organon (OGN) Q1 Earnings Expected to Decline
Zacks
8 days ago
Organon (OGN) Surpasses Market Returns: Some Facts Worth Knowing
CNBC
8 days ago
Not all dividend strategies are the same. How to choose the best one for you
Zacks
10 days ago
Organon (OGN) Beats Stock Market Upswing: What Investors Need to Know
Zacks
16 days ago
Should WisdomTree U.S. SmallCap Dividend ETF (DES) Be on Your Investing Radar?
Zacks
17 days ago
Organon (OGN) Advances While Market Declines: Some Information for Investors
Zacks
20 days ago
Molina (MOH) Wins Deal to Serve Michigan's Medicaid Members
Zacks
20 days ago
Play Safe! S&P 500 is Teasingly Close to its 50 DMA: 3 Picks
Zacks
23 days ago
Why HCA Healthcare (HCA) is a Smart Addition to Your Portfolio
Zacks
24 days ago
Why the Market Dipped But Organon (OGN) Gained Today
Yahoo
24 days ago
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
Yahoo
24 days ago
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
Zacks
a month ago
Encompass Health (EHC) Plans a 50-Bed Facility to Serve Texas
Zacks
a month ago
UnitedHealth (UNH) to Roll Out Medical Claims Software Soon
Zacks
a month ago
Here's Why You Should Retain Centene (CNC) Stock for Now
Zacks
2 months ago
Markets Dip but it's Time to Buy These Low-Risk High-Income Stocks
Zacks
2 months ago
Centene (CNC), Pearl Health Unite to Enhance Value-Based Care
Zacks
2 months ago
Here's Why You Should Add Cigna (CI) Stock to Your Portfolio
Zacks
2 months ago
Teladoc Health (TDOC) Unveils Solution to Ease Weight Loss
Yahoo
2 months ago
On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's health